TY - JOUR AU - Karachaliou, Niki AU - Fernandez-Bruno, Manuel AU - Paulina Bracht, Jillian Wilhelmina AU - Rosell, Rafael PY - 2018 TI - EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients JF - Translational Cancer Research; Vol 8, Supplement 1 (January 19, 2019): Translational Cancer Research (Targeted Therapy and Non-Small Cell Lung Cancer: A New Era?) Y2 - 2018 KW - N2 - Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutant NSCLC patients. This review will focus on the clinical development of first- and second-generation EGFR TKIs. We will emphasize on essential points like the head-to-head comparison among EGFR TKIs, their activity on brain metastases, mechanisms of resistance, as well as their combination with anti-angiogenic compounds, other targeted therapies, or immunotherapy. The efficacy of first- and second-generation EGFR TKIs in early-stage EGFR -mutant NSCLC will be also finally reviewed. UR - https://tcr.amegroups.org/article/view/24920